SURMOUNT-3 and SURMOUNT-4 Data

Oct 27, 2023, 03:21 PM

Headliner
Share
Subscribe
In this episode, hosts discuss the results of SURMOUNT-3 and SURMOUNT-4 as well as how it might help inform use of tirzepatide if approved by the US Food and Drug Administration for chronic weight management.
Share
Subscribe
Next
Diabetes Dialogue: Automated Insulin Delivery News in October 2023
Top episodes
Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Tirzepatide for Weight Loss and Lowering HbA1c with Juan Frias, MD
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Key Updates in ADA Standards of Care—2024
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives